現在表示しているページ
ホーム > 大学案内 > 教育情報の公表 > 各教員が有する学位及び業績 > 教員情報(山本 信之)
ここから本文です

教員情報

氏名 山本 信之(ヤマモト ノブユキ)
所属 内科学第三講座
職名 教授
連絡先
電話番号
073-441-0619
FAX番号
073-446-2877
E-mail
nbyamamo@wakayama-med.ac.jp
主な担当科目 呼吸器内科学
主な研究テーマ 肺癌に対する新規内科的治療方法の開発、Oncogenic driver Mutationを利用した個別化医療の実践、Circulating Tumor Cellや血中free DNAでのがん遺伝子の検討
研究分野
(キーワード)
呼吸器内科学、臨床腫瘍学、臨床薬理学、トランスレーショナルリサーチ
略歴 平成元年3月 和歌山県立医科大学卒業       
平成元年6月  和歌山県立医科大学付属病院臨床研修医
平成3年7月 那智勝浦町立温泉病院 内科   
平成4年6月  国立がんセンター中央病院内科レジデント
平成7年6月  国立がんセンター中央病院がん専門修練医  
平成9年4月 近畿大学医学部第四内科学助手
平成11年1月  近畿大学医学部第四内科学病院講師
平成14年4月  静岡県立静岡がんセンター呼吸器内科部長
平成23年1月 静岡県立静岡がんセンター副院長兼務
平成25年4月~   和歌山県立医科大学内科学第三講座教授
主な著書・論文
(最近3年間)
1. Inomata M, Yamamoto N, et al: Continuous Administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. Anticancer Research 31(12): 4519-4523, 2011

2. Kaira K, Yamamoto N, et al: L-type Amino Acid Transporter 1 (LAT1) Epression in Malignant Pleural Mesothelioma. Anticancer Research: 31(12): 4075-408, 2011

3. Kaira K, Yamamoto N, et al: LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. American Journal of Translational Research 3(5): 468-478, 2011

4. Kaira K, Yamamoto N, et al: Relationship between LAT1 Expression and Response to Platinum-based Chemotherapy in Non-Small Cell Lung Cancer Patients with Postoperative Recurrence. Anticancer Research 31(11): 3775-82, 2011

5. Takahashi T, Yamamoto N, et al: Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy. Oncology Letters 2(6): 1033-1040, 2011

6. Kaira K, Yamamoto N, et al: Prognostic Significance of Thymidylate Synthase Expression in the Adjuvant Chemothearpy after Resection for Pulmonary Metastases from Colorectal Cancer. Anticancer Research 31(9): 2763-71, 2011

7. Kaira K, Yamamoto N, et al: Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors. Oncology Reports 26(4): 931-937, 2011

8. Miura S, Yamamoto N, et al: Differential efficacy of docetaxel according to non-small-cell lung cancer histology and therapeutic effect of epidermal growth factor receptor-tyrosine kinase inhibitors. Oncology Letters 2(6): 1059-1064, 2011

9. Kenmotsu H, Yamamoto N, et al; The Risk of Cytotoxic Chemotherapy-Related Exacerbation of interstitial Lung Disease with Lung Cancer. Journal of Thoracic Oncology 6(7): 1242-1246, 2011

10. Shukuya T, Yamamoto N, et al: Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer 74(3): 457-61, 2011

11. Kaira K, Yamamoto N, et al: Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. Lung Cancer 74(3): 419-425, 2011

12. Kaira K, Yamamoto N, et al: Correlation Between 18F-FDG Uptake on PET and Molecular Biology in Metastatic Pulmonary Tumors. The Journal of Nuclear Medicine 52(5): 705-711, 2011

13. Ohyanagi F, Yamamoto N, et al: Safety of BLP25 Liposome Vaccine (L-BLP25) in Japanese Patients with Unresectable Stage III NSCLC after Primary Chemoradiotherapy: Preliminary Results from a Phase I/II Study. Japanese Journal of Clinical Oncology 41(5): 718-722, 2011

14. Kaira K, Yamamoto N, et al: MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. Virchow Archiv 458(5): 615-620, 2011

15. Kaira K, Yamamoto N, et al: Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and β III-Tubulin in Thymic Epithelial Tumors. Journal of Thoracic Oncology 6(3): 606-613, 2011

16. Akihiro Tamiya, Tateaki Naito*, Akira Ono, Eriko Ayabe, Asuka Tsuya, Yukiko Nakamura, Kyoichi Kaira, Haruyasu Murakami, Toshiaki Takahashi, Masahiro Endo, Nobuyuki Yamamoto: Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more. Lung Cancer 71(2): 173-177, 2011

17. Shukuya T, Yamamoto N, et al: Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports. Cancer Science 102(5): 1032-1037, 2011

18. Kaira K, Yamamoto N, et al: Biologic correlates of 18F-FDG Uptake on PET in pulmonary pleomorphic carcinoma. Lung Cancer 71(2): 144-150, 2011

19. Masuda N, Yamamoto N, et al: Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer. Cancer Chemotherapy Pharmacology 67(3): 533-42, 2011

20. Hida T, Yamamoto N, et al: Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer. Cancer Science 102(4): 845-851, 2011

21. Takahashi T, Yamamoto N, et al: Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemotherapy Pharmacology 68(3): 653-659, 2011

22. Okamoto I, Yamamoto N, et al: Single-agent gefitinib with concurrent radiotherapy for locally advanced non–small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer 72(2): 199-204, 2011

23. Kaira K, Yamamoto N, et al: 18F-FDG uptake on PET helps predict outcome and response after treatment in advanced thymic epithelial tumors. Annals Nuclear Medicine 25(4): 247-53, 2011

24. Kaira K, Yamamoto N, et al: 18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: A clinicopathological study. European Journal of Radiology 81(9): 2423-2429, 2012

25. Kaira K, Yamamoto N, et al: Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma. Medical Oncology 29(3): 1663-1672, 2012

26. Nakamura Y, T Yamamoto N, et al: Prognostic Factors and Clinical Outcome of Patients with Lung Adenocarcinoma with Carcinomatous Meningitis. Anticancer Research 32(5): 1811-1816, 2012

27. Atagi S, Yamamoto N, et al: Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group JCOG0301. Lancet Oncology 13(7):671-678, 2012

28. Tamiya A, Yamamoto N, et al: Interstitial Lung Disease Associated with Docetaxel in Patients with Advanced Non-small Cell Lung Cancer. Anticancer Research 32(3): 1103-1106, 2012

29. Kaira K, Yamamoto N, et al: The role of β III-tubulin in non-small cell lung cancer patients treated by taxanes-based chemotherapy. International Journal of Clinical Oncology, 2012 Feb 23. [Epub ahead of print]

30. Kaira K, Yamamoto N, et al: 18F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms? Neoplasma 59(2): 257-264, 2012

31. Kaira K, Yamamoto N, et al: Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. European Journal of Cancer 48(8): 1244-1254, 2012

32. Takahashi T, N Yamamoto N, et al: Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Investigatonal New Drugs 30(6): 2352-2363, 2012

33. Niho S, Yamamoto N, et al: Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76(3): 362-367, 2012

34. Shukuya T, Yamamoto N, et al: Comparison of Vinorelbine plus Cisplatin and S-1 plus Cisplatin in Concurrent Chemoradiotherapeutic Regimens for Unresectable Stage III Non-small Cell Lung Cancer. Anticancer Research 32(2): 675-680, 2012

35. Ono A, T Yamamoto N, et al: Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. Lung Cancer 76(3): 439-444, 2012

36. Goto K, Yamamoto N, et al: Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 7(1): 115-121, 2012

37. Naito T, Yamamoto N, et al: Prognostic impact of circulating tumor cells in patients with small-cell lung cancer. Journal of Thoracic Oncology 7(3): 512-519, 2012

38. Fukutomi A, Yamamoto N, et al: A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Investagational New Drugs 30(3): 1096-1106, 2012

39. Kaira K, Yamamoto N, et al: MUC1 Expression in Pulmonary Metastatic Tumors: A Comparison of Primary Lung Cancer. Pathology & Oncology Research 18(2): 439-447, 2012

40. Okamoto I, Yamamoto N, et al: Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non–small cell lung cancer. Investigational New Drugs 30(3): 1132-1137, 2012

41. Murakami H, Yamamoto N, et al: Phase I study of continuous Afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/Erlotinib/Gefitinib (LUX-Lung 4). Cancer Chemotherapy Pharmacology 69(4): 891-899, 2012

42. Harada H, Yamamoto N, et al: Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable locally-advanced non-small cell lung cancer; West Japan Thoracc Oncology Group WJTOG 3005-DI. International Journal of Radiation Oncology Biology Physics 82(5): 1777-1782, 2012

43. Kaira K, Yamamoto N, et al: Depolarized MUC1 expression is closely associated with hypoxic markers and poor outcome in resected non–small cell lung cancer. International Journal of Surgical Pathology 20(3): 223-232, 2012

44. Murakami H, Yamamoto N, et al: Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemotherapy Pharmacology 70(3): 407-14, 2012

45. Kenmotsu H, Yamamoto N, et al: Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: A retrospective study in Japan. Respiratory Investigation 50(4): 157-161, 2012.

46. Tokito T, Yamamoto N, et al: Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens. International Journal of Clinical Oncology 2012 Dec 19. [Epub ahead of print]

47. Shukuya T, Yamamoto N, et al: Chemoradiotherapy for Limited-disease Small-cell Lung Cancer in Elderly Patients Aged 75 Years or Older. Japanese Journal of Clinical Oncology 43(2): 176-183, 2013

48. Akamatsu H, Yamamoto N, et al: The impact of clinical outocomes according to EGFR mutation status in patients with locally adavanced lung adenocarcinoma who received concurrent chemoradio therapy. American Journal of Clinical Oncology, 2012 Dec 1. [Epub ahead of print]

49. Watanabe R, Yamamoto N, et al: Large Cell Neuroendocrine Carcinoma of the Lung: Is it Possible to Diagnose from Biopsy Specimens? Japanease Jouranal of Clinical Oncology 43(3): 294-304, 2013

50. Serizawa M, Yamamoto N, et al: Combined treatment with erlotinib and a transforming growth factor-b type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non–small-cell lung cancer cells. Journal of Thoracic Oncology 8(3): 259-69, 2013

51. Kiyota H, Yamamoto N, et al: Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for Advanced Adenocarcinoma of the Lung. Cancer Chemotherapy and Pharmacology 71(4): 859-865, 2013

52. Yoshioka H, Yamamoto N, et al: Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Annals of Oncology 24(5): 1326-1331.

53. Yamamoto N, et al: The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): Results from a phase I trial in advanced solid tumors. Annals of Oncology 24(5): 1653-1659, 2013

54. Okamoto I, Yamamoto N, et al: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer. Investigation New Drugs, 2013 Mar 10. [Epub ahead of print]

55. Wakuda K, Yamamoto N, et al: Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
American Journal of Clinical Oncology. 2013 Feb 5. [Epub ahead of print]

56. Satouchi M, Yamamoto N, et al: Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 81(1): 97-101, 2013.

57. Harada H, Yamamoto N, et al: Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non–small-cell lung cancer. Clinical Lung Cancer 14(4): 440-445, 2013.

58. Tokito T, Yamamoto N, et al: Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases. Cancer Chemotherapy Pharmacology 71(6): 1493-1498, 2013.

59. Akamatsu H, Yamamoto N, et al: Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two phase III trials (NEJ 002 and WJTOG3405). Japanese Journal of Clinical Oncology 43(6): 664-668, 2013.

60. Yoshihito K, Yamamoto N, et al: Histology and Smoking Status Predict Survival of Patients with Advanced Non-Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L
Journal of Thoracic Oncology 8(6):753-758, 2013.

61. Hosokawa M, Yamamoto N, et al: Microcavity Array System for Size-Based Enrichment of Circulating Tumor Cells from the Blood of Patients with Small-Cell Lung Cancer. Analytical Chemistry 85(12): 5692-5698, 2013 .

62. Niwakawa M, Yamamoto N, et al : Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors. Cancer Science 2013 May 16. doi: 10.1111/cas.12197. [Epub ahead of print]

63. Kurahashi I, Yamamoto N, et al: A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers
for Unknown Primary Cancer. PLoS One 8(5):e63249, 2013

64. Seto T,  Yamamoto N, et al: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncology S1470-2045(13)70142-6. doi:10.1016/S1470-2045(13)70142-6. [Epub ahead of print]

65. Imai H, T Yamamoto N, et al: Comparison of the time to response between radiotherapy and epidermal growth factor receptor - tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation. Anticancer Research, inpress

66. Hosokawa M, Yamamoto N, et al: Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System. PLoS One 8(6):e67466, 2013.

67. Sequist LV, Yamamoto N, et al: Phase III study of afatinib or cisplatin/pemetrexed in metastatic lung adenocarcinoma patients with epidermal growth factor receptor mutations. Journal of Clinical Oncology 2013 Jul 1. [Epub ahead of print].

68. Katakami N, Yamamoto N, et al: LUX-Lung 4: A Phase II Trial of Afatinib in Patients with Advanced, Non-Small Cell Lung Cancer who Progressed on Prior Treatment with Erlotinib, Gefitinib, or Both. Journal of Clinical Oncology 2013 Jul 1. [Epub ahead of print].

69. Yang JCH, Yamamoto N, et al: Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in advanced lung adenocarcinoma patients with epidermal growth factor receptor mutations. Journal of Clinical Oncology 2013 Jul 1. [Epub ahead of print].
学位 平成18年 医学博士 近畿大学医学部
受賞 平成7年 American Society of Clinical Oncology Merit Award
所属学会 American Society of Clinical Oncology:Member
European Society of Medical Oncology: Member
International Association for the Study of Lung Cancer:Member
2005年~2009年Board of Directors
日本臨床腫瘍学会:理事、評議員、Best of ASCO部会部会長
日本肺癌学会:理事、評議員、ガイドライン検討委員会副委員長、ガイドライン検委員会薬物療法および集学的治療小委員会委員長、学術委員会委員
日本癌学会:評議員
日本癌治療学会:日本癌治療学会がん診療ガイドライン委員会肺がん分科会協力委員
日本内科学会、日本呼吸器学会、日本呼吸器内視鏡学会
社会貢献活動 特になし